Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

Han Fu; Joseph A. Lewnard; Isabel Frost; Ramanan Laxminarayan; Nimalan Arinaminpathy

doi:10.1038/s41467-020-20731-x

Nature Communications (Jan 2021)

Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

Han Fu,
Joseph A. Lewnard,
Isabel Frost,
Ramanan Laxminarayan,
Nimalan Arinaminpathy

Affiliations

Han Fu: MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London
Joseph A. Lewnard: Division of Epidemiology, School of Public Health, University of California, Berkeley
Isabel Frost: Center for Disease Dynamics, Economics & Policy
Ramanan Laxminarayan: Center for Disease Dynamics, Economics & Policy
Nimalan Arinaminpathy: MRC Centre for Global Infectious Disease Analysis; and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London

DOI: https://doi.org/10.1038/s41467-020-20731-x
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 9

Abstract

Read online

Vaccines preventing tuberculosis disease progression have shown promising results in recent trials. Here, the authors use mathematical modelling to estimate that this type of vaccine could avert 10% of cases of rifampicin-resistant tuberculosis and 7% of deaths from 2020-2035.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal